PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsCobicistat
Stribild(cobicistat)
Cobicistat, Evotaz, Genvoya, Prezcobix, Rezolsta, Stribild, Symtuza, Tybost (cobicistat) is a small molecule pharmaceutical. Cobicistat was first approved as Stribild on 2012-08-27. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
BMS
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
urogenital diseasesD000091642
immune system diseasesD007154
Trade Name
FDA
EMA
Tybost (discontinued: Cobicistat)
Combinations
Evotaz, Genvoya, Prezcobix, Stribild, Symtuza
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cobicistat
+
Darunavir
Tradename
Company
Number
Date
Products
PREZCOBIXJohnson & JohnsonN-205395 RX2015-01-29
1 products, RLD, RS
Cobicistat
+
Darunavir
+
Emtricitabine
+
Tenofovir alafenamide fumarate
Tradename
Company
Number
Date
Products
SYMTUZAJohnson & JohnsonN-210455 RX2018-07-17
1 products, RLD, RS
Atazanavir sulfate
+
Cobicistat
Tradename
Company
Number
Date
Products
EVOTAZBristol Myers SquibbN-206353 RX2015-01-29
1 products, RLD, RS
Cobicistat
+
Elvitegravir
+
Emtricitabine
+
Tenofovir alafenamide fumarate
Tradename
Company
Number
Date
Products
GENVOYAGilead SciencesN-207561 RX2015-11-05
1 products, RLD, RS
Cobicistat
+
Elvitegravir
+
Emtricitabine
+
Tenofovir disoproxil fumarate
Tradename
Company
Number
Date
Products
STRIBILDGilead SciencesN-203100 RX2012-08-27
1 products, RLD, RS
Cobicistat
Tradename
Company
Number
Date
Products
TYBOSTGilead SciencesN-203094 RX2014-09-24
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
evotazNew Drug Application2023-05-12
genvoyaNew Drug Application2025-02-14
prezcobixNew Drug Application2024-07-23
stribildNew Drug Application2025-02-04
stribild accessExport only2021-03-29
symtuzaNew Drug Application2024-07-23
tybostNew Drug Application2025-01-14
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hiv infectionsEFO_0000764D015658B20
acquired immunodeficiency syndromeEFO_0000765D000163B20
chronic hepatitis bEFO_0004239D019694B18.1
hiv—D006678O98.7
Agency Specific
FDA
EMA
Expiration
Code
COBICISTAT, TYBOST, GILEAD SCIENCES INC
2026-08-22ODE-260
Patent Expiration
Patent
Expires
Flag
FDA Information
Cobicistat / Darunavir / Emtricitabine / Tenofovir Alafenamide Fumarate, Symtuza, Janssen Prods
107865182038-07-19U-2978
87540652032-08-15DS, DPU-257, U-2352, U-2765
92967692032-08-15DS, DPU-257, U-2352, U-2765
73907912025-01-07DS, DP
Atazanavir Sulfate / Cobicistat, Evotaz, Bristol
100397182032-10-06DP
81483742029-09-03DS, DPU-1279, U-2353, U-2364, U-2365, U-2766, U-2767, U-2768, U-2939
Cobicistat / Elvitegravir / Emtricitabine / Tenofovir Alafenamide Fumarate, Genvoya, Gilead Sciences Inc
86332192030-04-30DPU-257
98912392029-09-03DPU-257
76357042026-10-26DS, DPU-257
89811032026-10-26DS, DP
71762202026-08-27DS, DPU-257
Cobicistat / Darunavir, Prezcobix, Janssen Prods
77006452026-12-26DS, DP
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AR: Antivirals for treatment of hiv infections, combinations
— J05AR09: Emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat
— J05AR14: Darunavir and cobicistat
— J05AR15: Atazanavir and cobicistat
— J05AR18: Emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat
— J05AR22: Emtricitabine, tenofovir alafenamide, darunavir and cobicistat
V: Various drug classes in atc
— V03: All other therapeutic products
— V03A: All other therapeutic products
— V03AX: Other therapeutic products in atc
— V03AX03: Cobicistat
HCPCS
No data
Clinical
Clinical Trials
166 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B201152—8
Hiv-1D015497——2—21—5
Weight gainD015430—————1—1
InfectionsD007239EFO_0000544————1—1
Hiv seropositivityD006679—————1—1
ObesityD009765EFO_0001073E66.9———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Acquired immunodeficiency syndromeD000163EFO_0000765B20114——5
Immunologic deficiency syndromesD007153—D84.91—2——3
HivD006678—O98.7——1——1
PregnancyD011247EFO_0002950Z33.1——1——1
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———8————8
MalnutritionD044342EFO_0008572E40-E462————2
Crush injuriesD000071576—T14.81————1
Hiv-2D015498——1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCobicistat
INNcobicistat
Description
Cobicistat is a monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2S)-2-({[(2-isopropyl-1,3-thiazol-4-yl)methyl](methyl)carbamoyl}amino)-4-(morpholin-4-yl)butanoic acid with the amino group of 1,3-thiazol-5-ylmethyl [(2R,5R)-5-amino-1,6-diphenylhexan-2-yl]carbamate. Acts as a pharmacoenhancer in treatment of HIV-1 by inhibiting P450 enzymes that metabolise other medications.. It has a role as a P450 inhibitor. It is a member of 1,3-thiazoles, a member of morpholines, a member of ureas, a carbamate ester and a monocarboxylic acid amide.
Classification
Small molecule
Drug classenzyme inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1
Identifiers
PDB—
CAS-ID1004316-88-4
RxCUI—
ChEMBL IDCHEMBL2095208
ChEBI ID72291
PubChem CID25151504
DrugBankDB09065
UNII IDLW2E03M5PG (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Stribild – Gilead Sciences
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Genvoya – Gilead Sciences
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 4,070 documents
View more details
Safety
Black-box Warning
Black-box warning for: Genvoya, Stribild, Stribild access, Symtuza
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
14,906 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use